ClinicalTrials.gg
TerminatedNCT02862574Updated Jun 27, 2018Results posted

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

A Phase 2 interventional study of Andecaliximab and Placebo in Rheumatoid Arthritis, sponsored by Gilead Sciences. Terminated at 8 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated by sponsor and decision was not due to any safety signals.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Rheumatoid by Gilead Sciences — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Gilead Sciences.

Enrollment
11th of 12
15 · median 49
Started
2016
with 5 others
Phase 2
3 of 12
none open now
Registered
3rd of 12
by date

Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 11th largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 2, and was the 3rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 12 studies in Arthritis, Rheumatoid by Gilead Sciences is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Arthritis, Rheumatoid by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Tumor Necrosis Factor Inhibitor
  • TNF-IR
  • Methotrexate
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of RA (according to the 2010 American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) classification criteria) confirmed at screening
  • Must have taken oral or parenteral methotrexate (MTX) dosed from 7.5 to 25 mg/week continuously for at least 12 weeks and tolerated this medication, with at least 6 weeks of stable dose (defined as no change in prescription) prior to first dose of study drug
  • Individuals on MTX may also be on concurrent chloroquine or hydroxychloroquine at a stable dose (defined as no change in prescription) for at least 4 week prior to Baseline; if so, they should plan to continue this medication for the duration of the study
  • Must have an inadequate response to ≥ 12 weeks of ongoing treatment with an approved, stable subcutaneous (SC) formulation of TNF inhibitor (adalimumab, certolizumab pegol, etanercept, or golimumab), or marketed SC biosimilar TNF inhibitor with at least 6 weeks of stable dose (defined as no change in prescription), defined as: must have a DAS28(CRP) > 3.2 at screening AND must have ≥ 3 swollen and ≥ 3 tender joints (using the DAS28 joint counts) at screening and at baseline (do not need to be the same joints)
  • Non-steroidal anti-inflammatory drugs (NSAIDs) and/or oral (≤ 10 mg prednisone/day or equivalent) at a stable dose (defined as no change in prescription) for ≥ 4 weeks prior to baseline are allowed and throughout the blinded period of the study. PRN NSAID for indications other than RA are also allowed. (PRN means "pro re nata" or when necessary)
  • Tuberculosis (TB) Screening: Must meet either a. or b.:

    1. A negative history of TB infection and a negative QuantiFERON® TB-Gold In-Tube test and chest x-ray results. (QuantiFERON® tests with inconclusive results may be repeated one time. If the repeat result is also inconclusive, the individual will be excluded from the study).

      OR,

    2. Individuals with a history of latent TB treated with a full course of prophylaxis as per local guidelines are allowed per investigator judgment. It is the responsibility of the investigator to verify the adequacy of previous treatment and to provide appropriate documentation. In these cases, no QuantiFERON® test need be obtained. In addition, these cases must be approved by the medical monitor prior to enrollment. (Any new diagnosis of latent TB or prior untreated /partially treated latent TB in NOT allowed (ie, individuals who require prophylactic therapy for TB during the study). Any prior history of active TB [regardless of treatment] is exclusionary).
  • A negative chest x-ray (views per local guidelines) for active TB or other lung disease at screening; or a chest x-ray within 90 days of screening if films or report are available for investigator review

Key Exclusion Criteria:

  • Current treatment with any other disease modifying anti-rheumatic drug (DMARD) other than MTX, chloroquine or hydroxychloroquine, OR current treatment with other immune modulating/suppressive non-biologic and biologic medications as described in the study protocol
  • Intraarticular corticosteroid injection of any joint within 4 weeks of baseline
  • Any infection requiring oral antimicrobial therapy within 2 weeks prior to baseline
  • Current inflammatory joint disease, other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondylarthritis, or Lyme disease, OR other current diseases such as: systemic lupus erythematosus (SLE), inflammatory bowel disease, fibromyalgia, polymyalgia rheumatica, scleroderma, inflammatory myopathy, mixed connective tissue disease, or other overlap syndrome that would interfere with the evaluation of RA or require protocol prohibited medication (individuals with Sjogren's syndrome or controlled thyroiditis as defined by the investigator are not excluded)
  • Active systemic involvement secondary to RA such as vasculitis or Felty's syndrome
  • History of any of the following within 12 months of baseline:

    • infection requiring parenteral antibiotics or hospitalization
    • any life-threatening infection
    • sepsis
  • The results of the following laboratory tests performed at the central laboratory at screening meet any of the criteria below:

    • \< 8.0 g/dL (International System of Units (SI): \< 80 g/L)
    • White blood cells \< 3.0 x 10\^3 cells/mm\^3 (SI: \< 3.0 x 10\^9 cells/L)
    • Neutrophils \< 1.5 x 10\^3 cells/mm\^3 (SI: \< 1.5 x 10\^9 cells/L)
    • Lymphocytes \< 0.5 x 10\^3 cells/mm\^3 (SI: \< 0.5 x 10\^9 cells/L)
    • \< 100 x 10\^3 cells/mm\^3 (SI: \< 100 x 10\^9 cells/L)
    • (ALT) or aspartate aminotransferase (AST) ≥ 2 x (ULN)
    • Total level ≥ 2 x ULN unless the individual has been diagnosed with Gilbert's disease and this is clearly documented
    • Estimated \< 40 mL/min/1.73 m\^2 based on the Modification of Diet in Renal Disease (MDRD) formula
    • Positive serology during screening
    • Evidence of active Virus (HBV) infection
    • Evidence of active Virus (HCV) infection
  • Any uncontrolled laboratory abnormality that would affect interpretation of study data or the individual's participation in the study
  • or a history of malignancy or lymphoproliferative disorder within 10 years of screening with the following exceptions:

    • Carcinoma in situ of the cervix that has been successfully treated
    • Adequately treated basal or squamous cell cancer that has been successfully treated

Note: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Andecaliximab 300 mg

    Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.

    Drug: Andecaliximab · Drug: Methotrexate · Drug: TNF Inhibitor

  • Experimental
    Andecaliximab 150 mg

    Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.

    Drug: Andecaliximab · Drug: Placebo · Drug: Methotrexate · Drug: TNF Inhibitor

  • Placebo comparator
    Placebo

    Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.

    Drug: Placebo · Drug: Methotrexate · Drug: TNF Inhibitor

  • Experimental
    Open-Label Extension

    On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.

    Drug: Andecaliximab · Drug: Methotrexate · Drug: TNF Inhibitor

Interventions

  • Administered via subcutaneous injection once weekly

    Also known as: GS-5745

  • DrugPlacebo

    Administered via subcutaneous injection once weekly

  • Administered orally weekly as part of the participant's current treatment regimen

  • DrugTNF Inhibitor

    An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in DAS28(CRP) at Week 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Percentage of Participants That Achieve DAS28(CRP) ≤ 3.2 at Week 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Week 12

  2. Percentage of Participants That Achieve DAS28(CRP) < 2.6 at Week 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Week 12

  3. Plasma Concentration of Andecaliximab

    The plasma concentrations of andecaliximab were not collected and were not analyzed.

    Time frame: Day 4 or 6 (± 1 day)

07

Results

Posted Jun 27, 2018
Limitations and caveats
Gilead decided to discontinue the development of andecaliximab in RA and this study was terminated. The decision was not due to any safety concerns. Because only 15 participants were enrolled, no formal statistical testing was completed.

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 15 December 2016. The last study visit occurred on 07 August 2017.

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestoneAndecaliximab 300 mgAndecaliximab 150 mgPlacebo
Started555
Completed231
Not completed324
Withdrew: Adverse event010
Withdrew: Study terminated by sponsor314
Open-Label Treatment Period
Participant flow — Open-Label Treatment Period
MilestoneAndecaliximab 300 mgAndecaliximab 150 mgPlacebo
Started231
Completed000
Not completed231
Withdrew: Study terminated by sponsor231

Outcome measures

PrimaryChange From Baseline in DAS28(CRP) at Week 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Week 12
Reported as:
Mean · units on a scale
Change From Baseline in DAS28(CRP) at Week 12
units on a scaleAndecaliximab 300 mgAndecaliximab 150 mgPlacebo
Change From Baseline in DAS28(CRP) at Week 120.13 ± 0.115-1.51 ± 0.670-0.36 ± 0.353
SecondaryPercentage of Participants That Achieve DAS28(CRP) ≤ 3.2 at Week 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants That Achieve DAS28(CRP) ≤ 3.2 at Week 12
percentage of participantsAndecaliximab 300 mgAndecaliximab 150 mgPlacebo
Percentage of Participants That Achieve DAS28(CRP) ≤ 3.2 at Week 12000
SecondaryPercentage of Participants That Achieve DAS28(CRP) < 2.6 at Week 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants That Achieve DAS28(CRP) < 2.6 at Week 12
percentage of participantsAndecaliximab 300 mgAndecaliximab 150 mgPlacebo
Percentage of Participants That Achieve DAS28(CRP) < 2.6 at Week 12000
SecondaryPlasma Concentration of Andecaliximab

The plasma concentrations of andecaliximab were not collected and were not analyzed.

Time frame:
Day 4 or 6 (± 1 day)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to the last dose date (maximum: 127 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andecaliximab 300 mg (Double-Blind)0/5 (0%)0/5 (0%)3/5 (60%)
Andecaliximab 150 mg (Double-Blind)0/5 (0%)0/5 (0%)2/5 (40%)
Placebo (Double-Blind)0/5 (0%)0/5 (0%)2/5 (40%)
Andecaliximab 300 mg (Open-Label)0/6 (0%)1/6 (16.7%)2/6 (33.3%)
Most frequent serious events
Most frequent serious events
EventAndecaliximab 300 mg (Double-Blind)Andecaliximab 150 mg (Double-Blind)Placebo (Double-Blind)Andecaliximab 300 mg (Open-Label)
Pelvic painReproductive system and breast disorders0/50/50/51/6
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAndecaliximab 300 mg (Double-Blind)Andecaliximab 150 mg (Double-Blind)Placebo (Double-Blind)Andecaliximab 300 mg (Open-Label)
NauseaGastrointestinal disorders0/51/50/51/6
FatigueGeneral disorders1/50/50/50/6
InfluenzaInfections and infestations0/51/50/50/6
Upper respiratory tract infectionInfections and infestations0/51/51/50/6
White blood cell count decreasedInvestigations0/51/50/50/6
Pain in extremityMusculoskeletal and connective tissue disorders1/50/50/50/6
HeadacheNervous system disorders0/51/50/51/6
AnxietyPsychiatric disorders1/50/50/50/6
Rash papularSkin and subcutaneous tissue disorders0/50/51/50/6
Abdominal pain upperGastrointestinal disorders0/50/50/51/6

Baseline characteristics

Safety Analysis Set: participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Andecaliximab 300 mgAndecaliximab 150 mgPlaceboTotal
Mean54 ± 16.357 ± 9.358 ± 5.656 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Andecaliximab 300 mgAndecaliximab 150 mgPlaceboTotal
Female34411
Male2114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Andecaliximab 300 mgAndecaliximab 150 mgPlaceboTotal
Hispanic or Latino0202
Not Hispanic or Latino53513
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Andecaliximab 300 mgAndecaliximab 150 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2013
White35412
More than one race0000
Unknown or Not Reported0000
Disease Activity Score C-reactive Protein (DAS28(CRP))
Disease Activity Score C-reactive Protein (DAS28(CRP))(units on a scale)Andecaliximab 300 mgAndecaliximab 150 mgPlaceboTotal
Mean5.79 ± 0.8145.90 ± 0.7525.69 ± 0.8875.79 ± 0.764
08

Study locations

8 sites
  • Stanford University
    Palo Alto, California 94304, United States
  • Omega Research Consultants, LLC
    DeBary, Florida 32713, United States
  • G. Timothy Kelly, MD
    Las Vegas, Nevada 89128, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Tekton Research
    Austin, Texas 78728, United States
  • Accurate Clinical Research
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Jun 2017, 6 months.

Results were first posted in Jun 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 11, 2016
StartActual
Dec 15, 2016
Primary completionActual
Jun 26, 2017
CompletionActual
Aug 7, 2017
Results first posted
Jun 27, 2018
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02862574
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Dec 15, 2016
Primary completion
Jun 26, 2017
Completion
Aug 7, 2017
Results posted
Jun 27, 2018
Last update
Jun 27, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion